<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02380222</url>
  </required_header>
  <id_info>
    <org_study_id>BL7064A</org_study_id>
    <nct_id>NCT02380222</nct_id>
  </id_info>
  <brief_title>Patient-Reported Outcome Questionnaire for Systemic Mastocytosis</brief_title>
  <official_title>Patient-Reported Outcome Questionnaire Development for Symptoms of Systemic Mastocytosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adelphi Values LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Blueprint Medicines Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Adelphi Values LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore the key symptoms of individuals with systemic&#xD;
      mastocytosis. Interviews of enrolled individuals will be conducted to learn about the disease&#xD;
      symptoms and condition. The interview will last approximately 60 minutes and will be&#xD;
      conducted by a trained interviewer, be audio-recorded (with patient consent), and all&#xD;
      information provided by the patient will be treated confidentially and made anonymous so that&#xD;
      it is non-identifiable. The interview may be conducted face-to-face, over the phone, or&#xD;
      virtually via Skype, a free video conferencing program, depending upon the patient's&#xD;
      geographic location. Patients will be compensated for their participating time.&#xD;
&#xD;
      This is not a medication-related study, and no medication will be distributed or tested&#xD;
      during this study. Participation in this study will not affect any treatment or assistance&#xD;
      that a patient currently receives or may receive in the future.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Collection of qualitative interview data on the symptoms of advanced systemic mastocytosis</measure>
    <time_frame>Once</time_frame>
  </primary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Actual">5</enrollment>
  <condition>Aggressive Systemic Mastocytosis (ASM)</condition>
  <condition>SM w Assoc Clonal Hema Non-mast Cell Lineage Disease (SM-AHNMD)</condition>
  <condition>Mast Cell Leukemia (MCL)</condition>
  <condition>Smoldering Systemic Mastocytosis (SSM)</condition>
  <condition>Indolent Systemic Mastocytosis (ISM) ISM Subgroup Fully Recruited</condition>
  <arm_group>
    <arm_group_label>ASM</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>SM-AHNMD</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>MCL</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>SSM</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>ISM</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Interview</intervention_name>
    <description>Single interview lasting approximately one hour</description>
    <arm_group_label>ASM</arm_group_label>
    <arm_group_label>ISM</arm_group_label>
    <arm_group_label>MCL</arm_group_label>
    <arm_group_label>SM-AHNMD</arm_group_label>
    <arm_group_label>SSM</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Residents of the United States with advanced systemic mastocytosis who volunteer to&#xD;
        participate in the study&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Documented diagnosis of one of the following conditions based upon World Health&#xD;
             Organization (WHO) diagnostic criteria: aggressive systemic mastocytosis (ASM),&#xD;
             systemic mastocytosis with associated clonal hematologic non-mast cell lineage disease&#xD;
             (SM-AHNMD), mast cell leukemia (MCL), smoldering systemic mastocytosis (SSM), indolent&#xD;
             systemic mastocytosis (ISM)&#xD;
&#xD;
          -  Diagnosis confirmed by bone marrow biopsy&#xD;
&#xD;
          -  Fluency in English&#xD;
&#xD;
          -  Willingness and ability to participate in a one-hour interview&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A condition or situation that would interfere with participation in an interview&#xD;
             (e.g., cognitive impairment or disorder, alcohol or drug abuse)&#xD;
&#xD;
          -  Known human immunodeficiency virus or acquired immunodeficiency syndrome-related&#xD;
             illness&#xD;
&#xD;
          -  Any other prior malignancy except for the following: Adequately treated basal cell or&#xD;
             squamous cell skin cancer; In situ cervical cancer; Adequately treated Stage I or II&#xD;
             cancer from which the subject is currently in complete remission, or other cancer from&#xD;
             which the subject has been disease-free for 2 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Adelphi Values LLC</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>February 26, 2015</study_first_submitted>
  <study_first_submitted_qc>March 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2015</study_first_posted>
  <last_update_submitted>January 6, 2017</last_update_submitted>
  <last_update_submitted_qc>January 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Systemic mastocytosis</keyword>
  <keyword>Patient-reported outcome (PRO)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mastocytosis</mesh_term>
    <mesh_term>Mastocytosis, Systemic</mesh_term>
    <mesh_term>Leukemia, Mast-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

